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Prognostic genes have been well studied within each type of cancer. However, investigations
of the similarities and differences across cancer types are rare. In view of the optimal course
of treatment, classification of cancers into subtypes is critical to the diagnosis. We examined
the properties in gene co-expression networks using a patient-to-patient correlation network
analysis and a weighted gene correlation network analysis (WGCNA) for five cancer types
using data generated by UC Irvine. We further analyze and compare the degree, centrality
and betweenness of the network for each cancer type and apply a multinomial logistic re-
gression to identify the critical subset of genes. Given the cancer types provided, our study
presents a view of emergent similarities and differences across cancer types.
I. INTRODUCTION
Cancer describes a collection of diseases that share
some common characteristics, particularly unregulated
cell growth, they also vary widely in terms of mortality
rate, treatment options, and prevalence in the popula-
tion. Accurate diagnosis of cancer type is essential to de-
cide treatment options, therapy and prognoses. However,
some cancers are difficult to distinguish based on a single
test1. Gene expression microarray technology provides
precise information for cancer prognosis and treatment,
and has been used to categorize cancers into subgroups2.
Current classification methods include nearest prototype
classifier by defining subset of genes that best charac-
terize each class3, supervised classification algorithms to
identify gene expression signature, and the use of com-
bined algorithms4.
These methods have experienced moderate success, so
clearly the methods are identifying relevant statistical
differences in the tumor types in order to classify them
correctly. Digging one level deeper, we are interested to
explore the statistical differences between tumors, tying
them to phenotype differences in disease outcomes. Us-
ing this data-driven approach, we aim to understand the
variation within tumors of the same type as well as the
consistent differentiating features that distinguish each
tumor type.
A. Tumor Classification Background
Khan et al.1 explore the use of neural network classi-
fication models to classify cancer subtypes taking cDNA
expression data as the input. Their analysis was specific
to small blue-cell tumors (SBCTs) which can be further
classified into neuroblastoma (NB), rhabdomyosarcoma
(RMS), non-Hodgkin lymphoma (NHL) and the Ewing
family of tumors (EWS). Correct classification into sub-
types is critical to selecting the optimal course of treat-
ment. Usual methods for tumor classification often use
spectroscopy, but SBCTs are challenging to classify vi-
sually. There have been many attempts to use gene-
expression data to aid in classification, but so far none
have been proven to be effective in identifying cancers
that belong to several categories.
They started with a panel of 6567 genes from which
to find meaningful features. In order to make the dimen-
sionality of the data more manageable, they eliminated
genes that had expression levels below a threshold. With
the remaining 2308 genes, they performed PCA to further
reduce the dimensionality, taking the largest 10 compo-
nents which accounted for 63% of the variation. After
training on these features, their model was able to fit all
of the 63 samples from their training set. To identify the
most important genes, the authors altered each of the
locations to measure the overall classifications sensitivity
to that gene. After identifying the most important genes,
the authors performed multidimensional scaling (MDS)
to visualize the clear separation between cancers.
When they tested the models ability to classify new
samples, they were pleased to be able to classify all the
cancer types correctly. Unfortunately, they were unable
to reach the level of 95% confidence level in the diagnosis
that they were targeting. This highlights the challenge
of using machine learning methods in the medical field,
since clinical use needs highly reliable AI systems. This
study motivates further work of this kind with other dis-
ease types and larger data sets. Also, this result of a
reasonably successful classification method motivates our
analysis of the statistical properties of the different tu-
mor gene expression profiles, from which these classifiers
form decision boundaries.
B. Network Methods Background
Specifying features in genetics is a challenge because
there are often complicated interactions between genes.
To understand these relationships researchers have used
network models. Juan A. Botia et al.5 analyzed 1126
genes relating to 25 subtypes of Mendelian neurological
disease defined by Genomics England (March 2017) to-
gether with 154 gene-specific features capturing genetic
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2variation, gene structure and tissue-specific expression
and co-expression. He developed a technique to iden-
tify the gene mutations that can lead to a neurological
disorders. Random samples were selected with no dis-
ease association to develop decision tree models for each
subtype. Within the disorder subtypes, network models
were used to improve the predictive power.
Another instance of network approaches in genomes,
Yang et al.6 applied the weighted correlation network
analysis (WGCNA) method to construct a gene co-
expression network. In this study, they primarily in-
vestigated the prognostic genes that distinguish between
cancers. They investigated these genes with three dis-
tinct levels of depth properties: specific genes, gene mod-
ules, and the system holistically. At the gene level, they
found that network properties could distinguish prog-
nostic genes from other genes. More specifically, using
Fisher’s exact test, they were able to conclude that prog-
nostic genes tend not be hubs in the co-expression net-
work. On the gene modules level, they discovered that
prognostic genes are enriched significantly. Third, on
the system level, some prognostic modules are conserved
across tumour types.
II. PRELIMINARY METHODS
A. Dataset Description
The dataset is provided by University of California at
Irvine and is located here. The data includes 801 sam-
ples, each with 20,532 gene positions. Each sample vec-
tor contains the RNA-Seq gene expression levels. Each
sample in the dataset corresponds to a particular tumor
type. Every sample is one of five types: breast inva-
sive carcinoma (BRCA), kidney renal clear cell carcinoma
(KIRC), colon adenocarcinoma (COAD), lung adenocar-
cinoma (LUAD), and prostate adenocarcinoma (PRAD).
B. Understanding the data
(a) 2D PCA data projection (b) 3D PCA data projection
A preliminary analysis of our data is shown in Fig. 1a.
Not unusual in the genomics setting, we run into the
curse of dimensionality, making our 801× 20, 532 dimen-
sional matrix difficult to visualize. We performed Prin-
cipal Component Analysis on our data set and plotted
the projection of our data on the 2 principal components
with the largest corresponding eigenvalues in Figure 1a,
and the projection of our data on the 3 principal compo-
nents with the larges eigenvalues in Figure 1b. Prior
to performing the eigenvector decomposition, we pre-
process our data by subtracting the column mean from
the each entry. The result is the matrix X with dimen-
sion 801×20, 532 with each column having mean 0. Tak-
ing the eigenvector decomposition we get X = V ΛV T ,
where Λ is a diagonal matrix of the eigenvalues (sorted
such that the largest eigenvalue is in the top left) and V
has the corresponding eigenvectors as its columns. Tak-
ing the first d columns of V, we get Td = XVd, where T
has dimension n× d.
We compute T2 and T3 and plot the results. In both of
the plots, each point was colored according to what type
of cancer it represents. This further validates our intu-
itions that the each cancer type has particular features
that distinguish it from the others.
C. Variance of Tumor Types in Reduced Dimension
We aim to understand how the various tumor types
differ, both in statistical and phenotypic terms. The
previous PCA results show that projecting the samples
onto the first two or three principal components lead to
a reasonably clean separation. Interestingly, some cancer
types appear to be clustered more tightly together in this
lower dimensional space, while others appear to be more
loosely dispersed. Also, it is interesting to note which
pairs of tumor types appear closer together in this space.
To quantify both of these notions, we fit a Gaussian mix-
ture model to the PCA-transformed points. Using T2
from the previous section, we fit a five Gaussian mixture
that appears to closely approximate the true labeling of
the points. Sampling from a Gaussian mixture can be
thought of as a two step process. First, it involves sam-
pling from a multinomial distribution with parameters pi
(similar to an unfair dice). The result of the first step
determines which Gaussian to sample from in the second
step. Therefore, the conditional probability of the coor-
dinates of a sample, given it is a particular cancer type c,
is distributed according to N (µc, σ2c ). The second step is
simply to sample from that Gaussian. Gaussian mixture
models are fit using the expectation-maximization (EM)
algorithm, where the objective is to maximize the log-
likelihood of generating the training data. Fitting this
model results in the parameters pi, µ,Σ for each type of
cancer.
Assuming that this fit is reasonable, we can quantify
the notions of homogeneity within a tumor type by in-
specting the covariance matrix of the Gaussian corre-
sponding to that cluster of samples. Because we are in-
terested in the variance along the axis of the principal
components, we constrain the Gaussians to be oriented
along those axes (forcing the covariance matrices to be
diagonal). We get the following results where the vector
is ordered [LUAD, PRAD, KIRC, COAD, BRCA]:
piT =
(
0.23 0.16 0.18 0.08 0.35
)
µL =
(−1.60
51.24
)
, µP
( −54.91
−100.11
)
, µK =
(
151.45
−23.29
)
3µC =
(−19.50
120.05
)
, µB =
(−47.47
−1.81
)
ΣL = Diag
(
233.83
451.96
)
,ΣP = Diag
(
186.51
160.41
)
,
ΣK = Diag
(
594.35
235.63
)
,ΣC = Diag
(
92.20
224.27
)
,
ΣB = Diag
(
201.54
536.06
)
.
The model was able to fit the data reasonably well, which
can be seen in Figure 2. For example, the weights pi are
nearly the same distribution as the true labels which are:(
0.18 0.17 0.18 0.10 0.37
)
. Interestingly, we see that
KIRC has the largest variance in the first principal com-
ponent and BRCA has the largest variance in the second
principal component. Overall it appears that KIRC is the
most dispersed cancer type, since it has largest variance
on average over the 2-D space. This can be evidenced
in Figure 2, seeing that there are several samples that
are more than 2 standard deviations away from the clus-
ter mean. COAD and PRAD are the most concentrated,
suggesting that those samples are more homogeneous.
Note, that our model is not a perfect fit. Comparing
our fitted GMM model to the 2-D projection of the data
in Figure 1a, we see that some COAD samples are found
within the LUAD cluster. This GMM model does not
explain this feature of the data, motivating the use of
other methods to understand the gene expression profiles
of these cancer types.
FIG. 2: Above is the visualization of the gaussian mix-
ture model fit to explain the distribution of the samples
in the 2 dimensional space specified by the first principal
components. PRAD is blue, LUAD is purple, BRCA is
yellow, KIRC is teal, and COAD is green.
D. Stochastic Neighbor Embedding
In addition to PCA, we perform t-distributed stochas-
tic neighbor embedding to our data. tSNE is a proba-
bilistic approach to place objects from high-dimensional
space into low-dimensional space so as to preserve the
identity of the neighbors. Prior to tSNE, stochastic
neighbor embedding (SNE) was proposed, which used
the same general approach by placed a Gaussian on
each object in high-dimensional space. This resulted in
the “crowding problem” where many points would be
mapped together in the center. To overcome this prob-
lem, Hinton et al.7 proposed tSNE which has larger tails
and a steeper drop moving away from the mean (within
close range). Both methods are fit by minimizing the KL
divergence between the low and high dimensional proba-
bilities of picking a particular neighbor. Intuitively, this
method keeps “nearby” points in high dimension close to
each other in low dimensional space, while keeping sep-
arated points relatively far apart in the low dimensional
space. In this case tSNE is able to separate the tumor
types with high precision (notably better than PCA).
This result supports our intuition that different cancer
types are statistically distinguishable. For the rest of the
paper, we aim to characterize those statistical differences
more precisely.
FIG. 3: tSNE on our data gives the following well-
separated clusters
E. Hierarchical Clustering
Hierarchical clustering of gene expression is a popu-
lar mechanism to cluster genes with similar expression
patterns together. This clustering mechanism involves
calculation of distance between two gene vectors to find
the similarity between them. The dendrogram was sliced
at a height of 370 to find five clusters in particular. Fig-
ure 4 demonstrates the samples clustered into five clus-
ters where each cancer type is majorly clustered into just
one cluster. There seems to be one of the clusters that
consists of more than one cancer type, signifying that in
some patients the distance between the gene vectors is
close enough. These cancer types are BRCA, LUAD and
COAD. From figure 2 also it could be seen that these
three cancer types are close to each other.
4FIG. 4: Hierarchical clustering of the gene data set where
pink is KIRC, green is COAD, purple is BRCA, teal is
PRAD, and orange is LUAD.
III. NETWORK ANALYSIS
A. Patient-to-Patient Correlation Network
In order to understand the relationships between the
samples in our data set, we constructed a network with
each sample representing a node. The edges between S
samples are determined by the level of the correlation
between the G × 1 dimensional gene expression vectors.
We start with our data matrix A which is S × G. Our
correlation coefficients are defined as,
ρi,j =
∑G
k=1(Ai,k − µi)(Aj,k − µj)
σiσj
.
Given the correlation ρi,j between gene expression vector
for sample i with the gene expression vector for sample
j, we define a threshold value, drawing an edge between
sample i and sample j if the correlation is statistically sig-
nificant. We determine whether a correlation coefficient
is significant using the Fisher transformation, which con-
verts the distribution of Pearson’s correlation coefficients
to a normal distribution. This transformation takes the
following form:
Zi,j =
1
2
ln(
1 + ρi,j
1− ρi,j )
Using the transformed correlation coefficients we can ob-
tain a p-value from the Z-score, since they correspond to
the normal distribution. We chose the 5% significance
level to draw our edges in this graph. Figure 5 shows the
degree distributions of the networks created by the mech-
anism discussed above for each cancer type. The degree
distributions are left skewed suggesting that there are
many high degree nodes among all the 801 patients. This
also helps us conclude that the change in gene expression
levels is highly similar for patients within one cancer type.
Furthermore, the centrality measures are summarized in
Table I. These measures suggest that there are certain
patients that are central to the network corresponding to
the cancer type, and thus are representative samples. We
expect that adding more patients to the network would
change the degree distributions and centralities of each
patient. Then, depending on the degree measures of the
new patient relative to patients close to this new patient
who were already present in the network, we should be
able to classify these patients into groups that would re-
quire similar therapies.
(a) BRCA (b) KIRC
(c) LUAD (d) COAD (e) PRAD
FIG. 5: Degree distribution of network for each cancer
type
Cancer Degree Eigenvector Pagerank
PRAD 34,158,275,390 34,158,275,390 34
BRCA 99 111 99
LUAD 229 229 229
KIRC 423,591 376,591 376
COAD 26,237,264,665 665 237,264,665
TABLE I: Table summarizing nodes with max. Central-
ities
B. Weighted Gene Co-expression Network Analysis
A commonly used technique to analyze such data sets
is to create a Weighted Gene Co-expression Network8,9.
This is a graph which has genes as nodes and the edge
is given between two nodes represents the correlation be-
tween the two nodes that the edge joins. In order to
build such a network, we start by first splitting our data
set based on cancer type and then proceed with the cor-
relation computation as described above.
For the matrix containing the gene expressions for each
subset of our data, we compute the Pearson correlation
matrix, as shown above and then use that as our pre-
liminary adjacency matrix. Once we have computed the
matrix, we build the network by adding all the nodes,
but only draw edges if the correlation is above a value of
ρX,Y > 0.8. This threshold was chosen based on Fisher
exact test leads to a significance level of around 5%. Ad-
ditionally, it yields graphs that are sparse enough to visu-
alize, though also dense enough that will allow us to make
accurate computations. The networks resulting from this
method are shown in Figure 6. It is worth noting here
that creating such large networks, plotting and comput-
ing the centrality measures proved to be very computa-
tionally intensive, as they all had above 20,000 nodes and
5between 40,000 and 200,000 edges. Even when using a
powerful server (courtesy of the MIT Math Dep.), the
algorithms took hours to run for each of the networks.
(a) Breast cancer graph (b) Kidney cancer graph
(c) Lung cancer
graph
(d) Colon cancer
graph
(e) Prostate can-
cer graph
FIG. 6: WGCNs for each cancer type
It is interesting to note that even when only plotting
the edges above the 0.8 correlation threshold, the graphs
seem very dense. This is partially caused by the fact
that some genes are naturally correlated and would be
connected in the graph anyways. A way to go around
this would be to use the partial correlation matrix as the
adjacency matrix instead. The partial correlation would
effectively condition on the rest of the genes, resulting in
a more sparse network. However computing the partial
correlation proved to be much harder computationally,
or even impossible.
Once having the graphs, we first looked at the graph
statistics. The basic statistics are summarized in Ta-
ble II. Furthermore, we have plotted the histograms of
the degree distributions in Figure 7. We can see that that
the distributions seem to follow the power law. There
seem to be many nodes that have low degrees.
Network descriptions
Cancer Type # Nodes # Edges Avg. Degree
BRCA 20,259 43,475 4.28
KIRC 20,262 70,219 6.93
LUAD 20,251 58,963 5.82
COAD 20,227 201,408 19.91
PRAD 20,252 171,008 16.89
TABLE II: Basic statistics of the networks
(a) BRCA (b) KIRC
(c) LUAD (d) COAD (e) PRAD
FIG. 7: Degree histogram for each WGCN
After creating those graphs, we computed some cen-
trality measures, such as betweenness centrality, degree
centrality and pagerank centrality. The results we got
are summarized in tables Table III through Table VII,
where we can see the gene numbers that ranked higher
for each of the centrality measures we computed.
PRAD centralities
Order Degree Pagerank Betweenness
1 14,974 1,671 3,068
2 6,799 15,985 5,177
3 14,643 13,761 9,525
4 5,177 19,487 19,322
5 11,709 13,119 9,427
TABLE III: Centralities of PRAD WGCN
LUAD centralities
Order Degree Pagerank Betweenness
1 19,819 10,462 17,124
2 19,582 7,749 13,269
3 19,196 11,394 7,502
4 18,922 19,401 11,432
5 18,918 9 10,982
TABLE IV: Centralities of LUAD WGCN
BRCA centralities
Order Degree Pagerank Betweenness
1 15,512 14,974 19,862
2 14,376 17,430 4,749
3 3,356 16,274 14,974
4 8,355 19,847 20,355
5 1,139 715 1,511
TABLE V: Centralities of BRCA WGCN
6KIRC centralities
Order Degree Pagerank Betweenness
1 6,799 1,363 15,147
2 2,111 18,173 19,309
3 6,022 2,124 17,805
4 3,267 1,298 5,330
5 17,791 3,913 13,650
TABLE VI: Centralities of KIRC WGCN
COAD centralities
Order Degree Pagerank Betweenness
1 19,375 12,509 1,213
2 6,259 12,402 16,556
3 18,822 5,280 16,463
4 3,997 4 5,198
5 19,862 15,139 713
TABLE VII: Centralities of COAD WGCN
From this analysis, we can see what the most ”impor-
tant” genes are for each cancer type, based on their cen-
tralities. The genes with the highest centralities will be
the most prominent in patients with the respective type
of cancer, producing an outsize effect on the overall gene
expression. We could then try to map each of the gene
numbers to the actual gene name by ordering the gene
sequence and finding the gene corresponding to each in-
dex number. From there we could research the function
of that gene. We expect the function of the genes with
the highest centrality in each cancer type to be somehow
related to that organ in the body.
Furthermore, it is interesting to see that it is not the
case that the top 5 genes are the same in each centrality
measures. This happens because each centrality measure
is computed differently and will lead to different results.
Moreover, there is a very large amount of genes many of
whom have very similar values for their centrality scores
which means that even though one gene ranking highly in
one centrality measure could have a very high centrality
score in a different measure, it might still not make it in
the “top 5”.
Using the list of the gene names and mapping that
to the index given to us, we can find what gene name
each gene index number corresponds to. Then we can
search on the National Center for Biotechnology Infor-
mation (NCBI), we can find what exactly each gene does
and where it is most expressed. For example, the gene
with the highest pagerank centrality in LUAD (lung can-
cer) is gene #10,462 which corresponds to gene ”MACF1
23499”. NCBI tells us that this gene ”encodes a large
protein which is a member of a family of proteins that
form bridges between different cytoskeletal elements”.
Furthermore when we see in general this gene is mostly
expressed in lung tissue, as shown in figure 8. Further-
more gene #17,124 (highest betweenness in lung cancer)
or ”SPEN 23013” is a transcriptional repressor, which
would make sense to have high centrality that regulates
multiple genes expression that related to cancer.
FIG. 8: Gene expression comparison
Additionally, the gene with the highest degree central-
ity in colon cancer (VILL 50853), shows most expression
in the stomach area, intestines and colon, as shown in
Figure 9.
FIG. 9: Gene expression comparison
IV. CLUSTERS COMPARISON
A. Identifying the Critical Subset of Genes
We fit a multinomial logistic regression model to clas-
sify our data, estimating coefficients for each gene. Ana-
lyzing these coefficients, we can determine whether that
gene is a statistically significant determinant of a partic-
ular cancer type. Multinomial logistic regression is the
generalization of logistic regression to multiple categories.
Since we do not have normal samples in our dataset, we
use BRCA samples to indicate a baseline, since it is the
plurality of our samples. Fitting this model, we get both
coefficients and standard errors, and each number corre-
sponding to a model equation. For example, the first row
(COAD) for the gene# is regressed to the equation.
ln(
P (cancertype = COAD)
P (cancertype = BRCA)
) = β0 + β · gene#
The way to interpret this regression is that β means
one unit increase in gene# is associated with the de-
crease of probability in being COAD instead of BRCA
in the amount of β. To be more specific, the ratio of
the probability of choose one outcome category over the
probability of choose the baseline category is the right-
hand side linear equation exponentiated.
P (cancertype = COAD)
P (cancertype = BRCA)
= a · eβ·gene#
Thus, β are relative risk ratios for a unit change of
predictor variable. Since we have 801 samples data, this
7should provide a reasonably accurate estimate through
regression. We also got standard deviation from the re-
gression processes (for the coefficient) P-values were cal-
culated according to t-tests H0 : β = 0 vs.HA : β 6= 0.
After we got the P-values for all cancer types based on
breast cancer over 20532 genes. We chose the significance
level to be 0.005 and delete the genes with P-values below
this threshold in all 4 cancer types. The further analysis
is based on this small dataset. The − log(p) vs. gene#
were plotted (known as Manhattan plots) for each type
of cancer.
FIG. 10: Log(p) vs. Gene# of 4 cancer types
COAD,KIRC, LUAD, PRAD. Red line (log(p)=2.3) is
the threshold. Genes below this threshold were removed.
By choosing a threshold of p=0.005, log(p)=2.3. We
removed data below the red line in the plot. However,
according to the plots there are still lots of genes to be an-
alyzed. Interestingly, there are two narrow blank spaces
shown in all the plots and those parts may suggest that P
value are all large, and the cancer types has no relation-
ship with those genes. Thus, those genes can either be
genes related to this cancer (and are similar regulated in
all cancer types) or they can be genes unrelated to this
cancer (similar expressed for all people). This method
helped to reduce the set to 1075 genes, which we used for
the following analysis.
B. Clustering by Gene Expression Levels
Now with the smaller dataset, we want to analyze the
expression level of genes among different cancer types,
specifically we focused on LUAD and PRAD. They are
chosen since they have similar sample size. Before any
further analysis, the gene expressions were normalized
according to the average and standard deviation of that
specific gene expression in all cancer types.
The expression levels distributed according to the his-
tograms in LUAD, PRAD.
FIG. 11: Histogram of genes expression levels in LUAD.
A down-, B normal-, C over-, D highly expressed.
FIG. 12: Histogram of genes expression levels in PRAD.
a down-, b normal-, c over-, d highly expressed.
According to the graph, we think the expression could
be grouped into 5 groups, group A: (-10,-2), group B:
(-2,2), group C: (2, 8), group D: more than 8, with
other NA values to be group 0. This is consistent with
the down-regulated genes (compared with other cancer
types), normal-expressed genes, slightly over-expressed
genes, highly over-expressed genes. (This could be
changed according to the tissue type to make it more
biological meaningful.)
C. Conserved of Gene Expression Levels in LUAD and
PRAD
According to the groups, an adjacency matrix is gen-
erated with 1 at aij if both gene i and gene j are in same
8group, otherwise 0. This is then used to generate net-
work. We expected to see all the genes in same group
would be fully connected with each other, and a function
were used to separate the connected components apart.
The networks of LUAD and PRAD were shown as fol-
lowing.
FIG. 13: LUAD Network with gene in same label(A B C
D see Histogram) fully connected.
FIG. 14: PRAD Network with gene in same label(a b c
d see Histogram) fully connected with color of the nodes
consistent with LUAD labels
The nodes are colored according to the expression level
in LUAD cancer: group A as red, B as yellow, C as black
and D as blue (consistent with their labels in LUAD
histogram). The graphs suggest that in general, the
genes expressed highly in LUAD are distributed evenly
in PRAD, and especially group B and group C are mixed
evenly. Probably because the threshold choose is not sig-
nificant. However, there are some preservation of the
expression patterns.
V. DISCUSSION AND FURTHER WORK
Rank Type New Cases % Deadliest
1 Lung 2,093,876 12.3 1
2 Breast 2,088,849 12.3 3
3 Colorectal 1,800,977 10.6 2
4 Prostate 1,276,106 7.5 5
5 Stomach 1,033,701 6.1 n/a
TABLE VIII: Global cancer incidence10 where % refers
to the percent of new cases of cancer diagnosed in the
US in 2018 and deadliest refers to the ranking for that
cancer in causing the most deaths in 2018
Cancer is one of the most significant public health
challenges, particularly in the developed world. In this
project, we examined 4 of the top 5 (and 5 of the top 15)
cancer types in terms of new cases diagnosed in 2018,
evidenced by Table VIII. In addition to being prevalent,
the cancer types studied here correspond to 4 of the top
5 cancer types contributing to deaths in America. The
prevalence of datasets and computational tools has revo-
lutionized nearly all fields of science, particularly biology.
Transferring successful models from the statistical mod-
eling literature to this dataset has allowed us to validate
existing scientific conclusions and identify areas which
warrant further study. We were pleased to find that the
cancer types can be clustered into groups using out-of-
the-box approaches for dimensionality reduction. Since
each cancer type is different in many ways, it is reas-
suring to see those differences reflected in our statistical
approach. Other portions of our report highlight areas
that could be worth exploring further from the biomedi-
cal perspective. For example, in section 2.3, it was seen
that the 4 most prevalent and deadly cancer types ap-
peared clustered more closely together than to KIRC. It
would be interesting to explore how this matches the in-
tuition of oncologists, who might have a sense of which
cancer types are more similar to each other. Through
our network approaches we were able to identify genes of
interest. We are optimistic that these centrality measure
of our network correspond to biological insight and that
these network approaches can serve as a spotlight to help
guide researchers to study potentially high impact areas
of the genome in a more efficient manner.
VI. CONCLUSION
In this report we were able to summarize the similari-
ties and differences of 801 samples of 5 cancer types from
a dataset generated by UC Irvine. After performing an
exploratory analysis, we were surprised to see that the
gene expression profiles could be easily clustered. This
motivated further analysis to characterize interactions
between patients and genes that were indicative of bi-
ological differences between the cancer types. To charac-
terize these relationships we constructed networks: one
that represented the relationships between patients and
another that aimed to characterize the relationships be-
tween genes. Using standard network analysis measures
(such as centrality statistics) we highlighted genes that
appear to be highly influential for each cancer type, such
as MACF1 23499 for LUAD and VILL 50853 for COAD.
Both these genes appear to plausible genes involved with
these cancer types, validating elements of our approach.
These networks approaches and expression analyses ap-
plied gene expression data aim to motivate for future
work to understand the biological implications of stan-
dard statistical measures in gene expression profiles.
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